公开(公告)号：US09737586B2

公开(公告)日：2017-08-22

申请号：US14996440

申请日：2016-01-15

Applicant: University of Manitoba

Inventor： Michael P. Czubryt

IPC: A61K38/17 ,  C07H21/00 ,  C07K14/00 ,  C07K14/47 ,  C07K14/495

CPC classification number: A61K38/1709 ,  A61K38/17 ,  C07K14/4702 ,  C07K14/495

Abstract: Therapies and compositions for reducing collagen synthesis in mammalian cells and tissues wherein the targets are scleraxis, scleraxis-binding sites, receptor-regulated Smads, and/or binding sites for receptor-regulated Smads whereby synergistic interactions between scleraxis proteins and receptor-regulated Smads are reduced, inhibited, interfered with, stopped, and/or prevented thereby reducing, inhibiting and/or interfering with the activation of collagen 1α2 promoter thereby inhibiting collagen production in mammalian cells and tissues. Alternatively, the therapies and compositions may reduce, inhibit, interfere with, stop, and/or prevent binding of the collagen 1α2 promoter to DNA thereby inhibiting expression of the collagen 1α2 gene in mammalian cells and tissues.

公开(公告)号：US09238685B2

公开(公告)日：2016-01-19

申请号：US14355879

申请日：2012-11-05

Applicant: University of Manitoba

Inventor： Michael P. Czubryt

IPC: C07K14/00 ,  C07H21/00 ,  A61P43/00 ,  C07K14/495 ,  A61K38/17 ,  C07K14/47

CPC classification number: A61K38/1709 ,  A61K38/17 ,  C07K14/4702 ,  C07K14/495

Abstract: Therapies and compositions for reducing collagen synthesis in mammalian cells and tissues wherein the targets are scleraxis, sclerax-is-binding sites, receptor-regulated Smads, and/or binding sites for receptor-regulated Smads whereby synergistic interactions between scleraxis proteins and receptor-regulated Smads are reduced, inhibited, interfered with, stopped, and/or prevented thereby reducing, inhibiting and/or interfering with the activation of collagen 1α2 promoter thereby inhibiting collagen production in mammalian cells and tissues. Alternatively, the therapies and compositions may reduce, inhibit, interfere with, stop, and/or prevent binding of the collagen 1α2 promoter to DNA thereby inhibiting expression of the collagen 1α2 gene in mammalian cells and tissues.

Abstract translation: 用于减少哺乳动物细胞和组织中胶原合成的疗法和组合物，其中靶标是巩膜，巩膜结合位点，受体调节的Smads和/或受体调节Smads的结合位点，从而巩膜蛋白与受体调节之间的协同相互作用 Smads减少，抑制，干扰，停止和/或阻止，从而减少，抑制和/或干扰胶原1α2启动子的活化，从而抑制哺乳动物细胞和组织中的胶原产生。 或者，治疗和组合物可以减少，抑制，干扰，阻止和/或阻止胶原1α2启动子与DNA的结合，从而抑制胶原1α2基因在哺乳动物细胞和组织中的表达。

公开(公告)号：US20140288003A1

公开(公告)日：2014-09-25

申请号：US14355879

申请日：2012-11-05

Applicant: University of Manitoba

Inventor： Michael P. Czubryt

IPC: C07K14/495

CPC classification number: A61K38/1709 ,  A61K38/17 ,  C07K14/4702 ,  C07K14/495

Abstract: Therapies and compositions for reducing collagen synthesis in mammalian cells and tissues wherein the targets are scleraxis, scleraxis-binding sites, receptor-regulated Smads, and/or binding sites for receptor-regulated Smads whereby synergistic interactions between scleraxis proteins and receptor-regulated Smads are reduced, inhibited, interfered with, stopped, and/or prevented thereby reducing, inhibiting and/or interfering with the activation of collagen 1α2 promoter thereby inhibiting collagen production in mammalian cells and tissues. Alternatively, the therapies and compositions may reduce, inhibit, interfere with, stop, and/or prevent binding of the collagen 1α2 promoter to DNA thereby inhibiting expression of the collagen 1α2 gene in mammalian cells and tissues.

Abstract translation: 用于减少哺乳动物细胞和组织中胶原合成的疗法和组合物，其中靶标是巩膜，巩膜结合位点，受体调节的Smads和/或受体调节的Smads的结合位点，其中巩膜蛋白和受体调节的Smads之间的协同相互作用是 减少，抑制，干扰，停止和/或阻止，从而减少，抑制和/或干扰胶原1α2启动子的活化，从而抑制哺乳动物细胞和组织中的胶原产生。 或者，治疗和组合物可以减少，抑制，干扰，阻止和/或阻止胶原1α2启动子与DNA的结合，从而抑制胶原1α2基因在哺乳动物细胞和组织中的表达。

公开(公告)号：US20160303193A1

公开(公告)日：2016-10-20

申请号：US14996440

申请日：2016-01-15

Applicant: University of Manitoba

Inventor： Michael P. Czubryt

IPC: A61K38/17

CPC classification number: A61K38/1709 ,  A61K38/17 ,  C07K14/4702 ,  C07K14/495

Abstract: Therapies and compositions for reducing collagen synthesis in mammalian cells and tissues wherein the targets are scleraxis, scleraxis-binding sites, receptor-regulated Smads, and/or binding sites for receptor-regulated Smads whereby synergistic interactions between scleraxis proteins and receptor-regulated Smads are reduced, inhibited, interfered with, stopped, and/or prevented thereby reducing, inhibiting and/or interfering with the activation of collagen 1α2 promoter thereby inhibiting collagen production in mammalian cells and tissues. Alternatively, the therapies and compositions may reduce, inhibit, interfere with, stop, and/or prevent binding of the collagen 1α2 promoter to DNA thereby inhibiting expression of the collagen 1α2 gene in mammalian cells and tissues.

Abstract translation: 用于减少哺乳动物细胞和组织中胶原合成的疗法和组合物，其中靶标是巩膜，巩膜结合位点，受体调节的Smads和/或受体调节的Smads的结合位点，其中巩膜蛋白和受体调节的Smads之间的协同相互作用是 减少，抑制，干扰，停止和/或阻止，从而减少，抑制和/或干扰胶原1α2启动子的活化，从而抑制哺乳动物细胞和组织中的胶原产生。 或者，治疗和组合物可以减少，抑制，干扰，阻止和/或阻止胶原1α2启动子与DNA的结合，从而抑制胶原1α2基因在哺乳动物细胞和组织中的表达。